Overview

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Status:
Recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to <18 years old).

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Eliglustat